CAMBRIDGE, Mass. & MONTREAL --(BUSINESS WIRE)--Jun. 23, 2020-- Repare Therapeutics Inc. (Nasdaq: RPTX), a leading precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today announced the closing of its previously
CAMBRIDGE, Mass. & MONTRÉAL --(BUSINESS WIRE)--Jun. 18, 2020-- Repare Therapeutics Inc. (Nasdaq: RPTX), a leading precision oncology company enabled by our proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today announced the pricing of its upsized
Bristol Myers Squibb to leverage Repare’s proprietary SNIPRx® synthetic lethal discovery platform to identify multiple oncology drug candidates $65 million upfront payment including $15 million in equity investment Repare Therapeutics eligible to receive development, regulatory and commercial
